Skip to main content

Table 4 Correlations between clinicopathological features and BCOR expression in all the included cases

From: The values of Transgelin, Stathmin, BCOR and Cyclin-D1 expression in differentiation between Uterine Leiomyosarcoma (ULMS) and Endometrial Stromal Sarcoma (ESS); diagnostic and prognostic implications

Characteristics

All (N = 44)

BCOR

   
  

Negative (N = 23)

Focal weak +ve (N = 7)

Diffuse strong +ve (N = 14)

p-value

 

No. (%)

No. (%)

No. (%)

No. (%)

 

Age (years)

 Mean ± SD

56.84 ±7.93

62.52 ±4.98

51 ±7.85

50.42 ±4.23

<0.001*

 Median (Range)

57 (39-72)

62 (56-72)

51 (39-60)

50 (44-60)

 

 ≤ 55 years

18 (40.9%)

0 (0%)

5 (27.8%)

13 (72.2%)

<0.001‡

 > 55 years

26 (59.1%)

23 (88.5%)

2 (7.7%)

1 (3.8%)

 

Histopathology

 LMS

22 (50%)

19 (86.4%)

2 (9.1%)

1 (4.5%)

<0.001‡

 ESS

22 (50%)

4 (18.2%)

5 (22.7%)

13 (59.1%)

 

Grade

 Grade I

9 (20.5%)

9 (100%)

0 (0%)

0 (0%)

<0.001‡

 Grade II

12 (27.3%)

6 (50%)

6 (50%)

0 (0%)

 

 Grade III

23 (52.3%)

8 (34.8%)

1 (4.3%)

14 (60.9%)

 

Extrauterine extension

 Absent

6 (13.6%)

6 (100%)

0 (0%)

0 (0%)

0.007‡

 Present

9 (20.5%)

7 (77.8%)

2 (22.2%)

0 (0%)

 

 N/A

29 (65.9%)

10 (34.5%)

5 (17.2%)

14 (48.3%)

 

LVSI

     

 Absent

21 (47.7%)

15 (71.4%)

5 (23.8%)

1 (4.8%)

0.001‡

 Present

23 (52.3%)

8 (34.8%)

2 (8.7%)

13 (56.5%)

 

Other pelvic organ invasion

 Absent

15 (34.1%)

9 (60%)

5 (33.3%)

1 (6.7%)

0.010‡

 Present

29 (65.9%)

14 (48.3%)

2 (6.9%)

13 (44.8%)

 

Adnexal invasion

 Absent

11 (25%)

11 (100%)

0 (0%)

0 (0%)

0.001‡

 Present

33 (75%)

12 (36.4%)

7 (21.2%)

14 (42.4%)

 

Lymph node

 Negative

16 (36.4%)

14 (87.5%)

2 (12.5%)

0 (0%)

0.001‡

 Positive

28 (63.6%)

9 (32.1%)

5 (17.9%)

14 (50%)

 

Distant metastasis

 Absent

29 (65.9%)

19 (65.5%)

7 (24.1%)

3 (10.3%)

<0.001‡

 Present

15 (34.1%)

4 (26.7%)

0 (0%)

11 (73.3%)

 

FIGO Stage

 Stage I

6 (13.6%)

6 (100%)

0 (0%)

0 (0%)

<0.001‡

 Stage II

10 (22.7%)

8 (80%)

2 (20%)

0 (0%)

 

 Stage III

13 (29.5%)

5 (38.5%)

5 (38.5%)

3 (23.1%)

 

 Stage IV

15 (34.1%)

4 (26.7%)

0 (0%)

11 (73.3%)

 

Stathmin

 Negative

19 (43.2%)

4 (21.1%)

5 (26.3%)

10 (52.6%)

0.007‡

 Focal weak +ve

12 (27.3%)

10 (83.3%)

0 (0%)

2 (16.7%)

 

 Diffuse strong +ve

13 (29.5%)

9 (69.2%)

2 (15.4%)

2 (15.4%)

 

Transgelin

 Negative

25 (56.8%)

7 (28%)

5 (20%)

13 (52%)

0.004‡

 Focal weak +ve

6 (13.6%)

6 (100%)

0 (0%)

0 (0%)

 

 Diffuse strong +ve

13 (29.5%)

10 (76.9%)

2 (15.4%)

1 (7.7%)

 

Cyclin-D1

 Negative

24 (54.5%)

21 (87.5%)

2 (8.3%)

1 (4.2%)

<0.001‡

 Focal weak +ve

5 (11.4%)

2 (40%)

3 (60%)

0 (0%)

 

 Diffuse strong +ve

15 (34.1%)

0 (0%)

2 (13.3%)

13 (86.7%)

 
  1. * Kruskal Wallis H test; ‡ Chi-square test; p < 0.05 is significant
Back to article page

Surgical and Experimental Pathology

ISSN: 2520-8454

Contact us